Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BeiGene Ltd ( (HK:6160) ) just unveiled an announcement.
BeOne Medicines Ltd., formerly known as BeiGene, Ltd., has officially changed its English company name and stock short name as part of its strategic rebranding efforts. The change, effective from May 27, 2025, reflects the company’s new identity and is confirmed by the Registrar of Companies in Hong Kong. The English stock short name for trading on the HKEX will be updated to ‘BEONE MEDICINES’ starting October 22, 2025, while the stock code remains ‘06160’. This rebranding is a significant step in the company’s evolution and may influence its market presence and stakeholder engagement.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$236.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,054,047
Technical Sentiment Signal: Buy
Current Market Cap: HK$285.3B
See more insights into 6160 stock on TipRanks’ Stock Analysis page.